Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

IQ/OQ/PQ Protocol Remediation for Inspection-Ready Equipment Qualification

A German pharmaceutical manufacturer hired Zamann Pharma Support after FDA and EMA auditors repeatedly questioned its equipment qualification program.

The company had dozens of completed, signed, and archived Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ) protocols. However, the documentation lacked the scientific justification and traceability needed to demonstrate equipment fitness for intended use.

As a result, the manufacturer faced recurring regulatory concerns despite having extensive qualification records.

Our team reviewed the qualification documentation, interviewed equipment users and validation staff, and identified the critical gaps affecting the manufacturer’s qualification strategy.

Challenges Faced

A detailed GAP analysis in Quality Management Systems is essential for identifying process deficiencies effectively.
  • Missing URS Traceability and Scientific Justification: Protocols lacked links between URS, CQAs, CPPs, risk assessments, and tests, weakening evidence of equipment suitability.
  • Insufficient OQ Testing: OQ tests covered nominal conditions but insufficiently challenged operating limits, alarms, interlocks, emergency stops, and fail-safe functions.
  • Unrepresentative PQ Conditions: PQ used smaller batches, simplified workflows, shorter runs, and limited worst-case testing, with weak links to product quality data.
  • Inadequate Deviation Management:Skipped tests, failed criteria marked as passing, undocumented corrections, and missing root cause assessments raised GMP concerns.
  • Incomplete Qualification Reports: Reports lacked clear results, test traceability, deviation assessments, and evidence-based conclusions.
  • Regulatory and Operational Risks: Weak qualification evidence increased regulatory scrutiny and risks of requalification, additional costs, production delays, and supply disruption.

Zamann Pharma Support’s Approach

  • Run a Quick IQ/OQ/PQ Risk Self-Diagnostic: Eight yes/no questions test URS traceability, OQ ranges, alarms, boundary testing, PQ batch sizes, CQA-based criteria, deviations, and reporting. Seven to eight “yes” answers mean a strong system, four to six moderate concern, and zero to three high risk.
  • Align the Qualification Strategy With GAMP 5 and Annex 15: The strategy must be risk-based, traceable, lifecycle-oriented, and tied to intended use, per 21 CFR 211.63, 211.67, 211.68, Annex 15, Annex 11, EU GMP Part I, and GAMP 5. FDA warning letters often cite incomplete testing, poor documentation, unchallenged ranges, and poor PQ.
  • Build a Traceability Matrix Before Writing Protocols: A matrix built first covers every URS item and risk. It also impresses regulators.
  • Strengthen OQ With Challenge Tests: OQ should test min/max loads, temperature extremes, and speed and pressure limits. It must also cover alarms, interlocks, fail-safes, and negative tests.
  • Reinforce PQ Under Worst-Case Conditions: PQ must simulate real-world worst-case conditions. That means the largest batches, longest runs, hardest products, and full workflows.
  • Improve Reporting and Documentation: Reports need raw data references, justified deviations, risk assessments, and summary tables. They must end with a clear qualified/not qualified conclusion and QA sign-off.
  • Train Personnel on Protocol Execution: Staff must know how to follow test steps, record data, document deviations, and handle unexpected responses. Without training, qualification often fails.

Results Achieved

  • Greater Manufacturing Reliability and Less Downtime: Strong qualification improves manufacturing reliability and reduces downtime.
  • Stronger Product Quality: It also strengthens product quality.
  • Faster Investigations and Technology Transfer: Moreover, it supports faster investigations and accelerates technology transfer.
  • Lower Audit Risk and Greater Inspection Resilience: Strong qualification reduces audit risk, and companies with strong frameworks perform better operationally and are more resilient during inspections.
  • A Foundation for Digital Transformation: In highly automated manufacturing, qualification rigor signals organizational maturity and is a prerequisite for digital transformation.
Laboratory
GMP qualification and lifecycle validation activities including IQ, OQ, and PQ supporting inspection readiness in pharmaceutical manufacturing.
Services

Qualification and Validation for GMP Systems

Our team supports the planning, execution, and maintenance of qualification and validation activities, including IQ, OQ, and PQ, to keep GMP-regulated systems compliant and under control.

Read More

Contact Us

Need help? Don't hesitate to get in touch
Zamann pharma support is committed to protecting and respecting your privacy, and we’ll use your personal information to administer your account and to provide the products and services you requested from us.

FAQ

1. Why does PQ fail FDA or EMA inspection when the equipment clearly works?

PQ fails when it proves the equipment works, but not that it works for your process. Regulators expect PQ to simulate worst-case conditions (largest batches, longest runs, most difficult products, full workflows) linked to product quality data. Accordingly, EMA cites PQ performed on reduced batch sizes, and FDA 483s cite PQ that did not represent typical or worst-case operating conditions.

2. How do you trace URS requirements to IQ/OQ/PQ acceptance criteria?

Link the URS to CQAs/CPPs, the risk assessment, the IQ/OQ/PQ tests, and the acceptance criteria. Then build a traceability matrix before writing protocols, so every URS item and risk is covered with no testing gaps. Without this chain, regulators see a systemic validation failure, and EMA cites missing traceability between URS and qualification tests.

3. What must OQ challenge to meet FDA and EU GMP Annex 15 expectations?

OQ must challenge the full operational range, not just nominal conditions: min/max limits and loads, temperature extremes, speed and pressure limits, alarms, interlocks, emergency stops, fail-safes, process variability, and negative tests. Annex 15 demands risk-based protocols, while FDA 483s cite OQ that did not evaluate critical alarm functions and EMA cites missing OQ acceptance criteria.